WITH different countries
adopting different name standards
for the same medicinal molecule,
Therapeutic Goods Administration
(TGA) has alerted healthcare
professionals that some drug
names in Australia are obsolete.
The TGA has said it intends to
update some medicine ingredient
names used in Australia to align
with names used internationally.
Similar harmonisation activities
have previously occurred in the UK
(2003) and NZ (2008).
Using a four-year transition period
for these changes, from Apr 2016 to
Apr 2020, the TGA says the changes
will be more easily adopted by the
medical community and errors
avoided, with both names required
to be used on labelling for a further
three years to 2023 - eg., ‘lidocaine
(lignocaine)’.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Feb 16
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.